摘要
目的:探讨抗CD137抗体是否能加强树突状细胞疫苗的抗肿瘤效应。方法:将Renca肾癌细胞注入Balb/c小鼠皮下。3天后,小鼠被随机分为4组,分别给予未治疗、树突状细胞疫苗治疗、抗CD137抗体治疗、树突状细胞疫苗联合抗CD137抗体治疗。肿瘤种植后20天,小鼠被处死,获取脾脏分析T细胞活性。通过测量肿瘤大小来评定抗肿瘤效应。结果:相比于未治疗,各种治疗显著增加了T细胞活性,抑制了肿瘤生长,尤以联合治疗的作用为最强。结论:联合治疗通过增加T细胞活性来提高抗肿瘤效应。
[Objective] To investigate whether anti-CD137 antibody can potentiate antitumor effect of dendritic cell(DC) vaccine.[Method] A renal cell carcinoma model was established by subcutaneous injection of Renca tumor cells into Balb/c mice.After 3 days,tumor-bearing mice were not treated or treated with DC vaccine,anti-CD137 antibody,or both combinations.Mice were killed on day 20 after tumor cell inoculation,and spleens were harvested for analysis of T cell activity.The antitumor effect was assessed by measuring tumor size.[Result] Compared with un-treatment,different treatments significantly increased T-cell activity,and inhibited tumor growth,with the highest effect in combination therapy.[Conclusion] Combination therapy can enhance antitumor effect by increasing T-cell activity.
出处
《浙江医学教育》
2012年第4期47-50,共4页
Zhejiang Medical Education
基金
浙江省钱江人才计划基金资助项目(文件号:浙人社发[2009]194号)
浙江省教育厅科学基金资助项目(编号:Y200805942)
